Physician profile
Shumin Zhen
NPI 1043486491
$7,949.51
in general payments reported to CMS, 2019-2025
36 companies · $1,691 in 2025
The $1,691 reported for 2025 was more than what 93% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,534 · 2022: $1,837 · 2023: $1,382 · 2024: $1,505 · 2025: $1,691.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,579.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,578.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,485.96 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $714.53 | 2021-2025 | Jardiance |
| Aop Health US, LLC | $572.36 | 2025 | Rapiblyk |
| Pfizer INC. | $519.05 | 2021-2025 | |
| Amgen INC. | $490.12 | 2021-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals Lp | $420.49 | 2021-2025 | Wainua, Farxiga |
| Alnylam Pharmaceuticals INC. | $403.20 | 2021-2025 | Amvuttra |
| Lexicon Pharmaceuticals, INC. | $387.95 | 2023-2024 | Inpefa |
| Merck Sharp & Dohme LLC | $373.07 | 2022-2025 | Verquvo, Winrevair |
| Janssen Pharmaceuticals, INC | $301.45 | 2021-2024 | Xarelto |
| Actelion Pharmaceuticals US, INC. | $266.67 | 2021-2025 | Uptravi, Opsumit |
| Penumbra, INC. | $234.54 | 2022 | |
| Esperion Therapeutics, INC. | $231.77 | 2021-2023 | Nexletol |
| Abbott Laboratories | $228.81 | 2021-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Kiniksa Pharmaceuticals, Ltd. | $190.52 | 2021-2023 | Arcalyst |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $180.63 | 2021-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $121.78 | 2024 | Arcalyst |
| United Therapeutics Corporation | $93.18 | 2022-2025 | Orenitram, Remodulin |
| Kestra Medical Technology Services, INC. | $82.95 | 2025 | Assure Wcd |
| Abiomed | $82.01 | 2024-2025 | Impella |
| Lilly USA, LLC | $81.43 | 2023-2024 | Zepbound, Mounjaro |
| Inspire Medical Systems, INC. | $78.43 | 2024-2025 | Inspire |
| Amarin Pharma, INC. | $65.10 | 2021 | |
| Boston Scientific Corporation | $55.20 | 2021 | |
| Astellas Pharma US INC | $37.36 | 2022 | |
| Endotronix, INC. | $35.33 | 2025 | Cordella Pulomonary Artery Pressure Sensor |
| W. L. Gore & Associates, INC. | $33.38 | 2024-2025 | Gore Cardioform Septal Occluder |
| E.R. Squibb & Sons, L.L.C. | $26.59 | 2024 | Eliquis |
| Sobi, INC | $25.54 | 2022 | |
| Edwards Lifesciences Corporation | $24.51 | 2021 | |
| Irhythm Technologies, INC. | $20.91 | 2023 | Zio Xt Patch |
| Novo Nordisk INC | $20.24 | 2023 | Ozempic, Rybelsus |
| Kowa Pharmaceuticals America, INC. | $17.16 | 2021 | |
| Scpharmaceuticals INC. | $16.71 | 2023 | |
| Atricure, INC. | $15.67 | 2021 | |
| Heartflow, INC. | $14.91 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shumin Zhen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.